Furthermore, serum IGF-I levels were found to be decreased in patients with NAFLD11 and decreased IGF-I levels were associated with inflammation and fibrosis12, 13, suggesting that a decrease in serum IGF-I levels may play a role in the development of NAFLD/NASH in a general population. The gene discussed is IGF1; the disease is metabolic dysfunction-associated steatotic liver disease.